Insilico Medicine Inc. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of obesity, autoimmune disease and inflammatory disorders.

EA Pharma Co. Ltd. has prepared and tested nitrogen-including heterocycle derivatives acting as 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD) inhibitors.

University of Miami has patented new vasopressin V1A receptor antagonists reported to be useful for the treatment of osteoporosis, Paget disease and cancer.

Insitro Inc. has signed three strategic agreements with Eli Lilly & Co. focused on advancing potential new medicines for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), based on targets identified by Insitro using its artificial intelligence/machine learning-based platform.

Cascade Pharmaceuticals Inc. has synthesized benzoheterocyclic compounds acting as free fatty acid FFA1 receptor (GPR40) agonists reported to be useful for the treatment of diabetes.